By Steve Edelson
Staff Writer

Afferon Corp. is developing vanilloid compounds with a focus on urology. The company believes that its lead product, resiniferatoxin (RTX), has advantages over marketed treatments for urge incontinence in both side effect profile and compliance issues. And with plans this week to announce a deal with Mundipharma in the U.K. that could be worth up to $100 million, Afferon said it has the necessary funding to get to market without having to "venture" to the Street.